• 0756-8800024
  • Address
  • Mailing Form
  • Languages
    English
    • 中文简体
    • 中文繁體
    • Indonesia
    • Tiếng Việt
    • ภาษาไทย
    • Português
Home
  • About Us
  • Refractory Diseases
  • Expert Team
  • Treatment Cases
  • Outpatient Rehabilitation
  • Functional Food
  • Cell Products
  • Service Centre
  • Contact Us
> Home > Expert Team > Team Of Overseas Experts > Lynn Hlatky
  • Expert Team
  • Team Of Overseas Experts
  • Team Of Chinese Experts
  • Why choose us?
  • The First Cell Science Center Dedicated to Refractory Diseases
    Led by Nobel Laureate Dr. Randy Schekman and a global MDT expert team
    With over 10,000 successful clinical cases of hard-to-treat diseases accumulated over more than a decade
    Providing high-quality medical services in a warm and comfortable environment
  • Treatment Cases
      • Mr. Zhao’s Story: Rebuilding Confidence i
      • Pancreatic Cancer "Breaker": The Immune Rec
      • Reigniting Confidence: Mr. Lin's S
  • 400-830-8005
    0756-8800024
    NO.66,YIWEN 1,HENGQIN NEW DISTRICT,ZHUHAI CITY,GUANGDONGPROVINCE,CHINA
Lynn Hlatky
Lynn Hlatky
Title:
Director
Position:
Department of Cancer, Tufts University
Expertise:
Radiobiology, Cancer Biology
Click For consultation
Hot Line 400-830-8005

Profile:

Dr. Hlatky received her Ph.D. in Physics and Biophysics from the University of California, Berkeley in 1985. During her time at Berkeley, she was funded by the National Cancer Institute, and the cancer models she developed using physics became industry standards. She served as a faculty member in the Department of Radiation and Oncology at Harvard University for 16 years, where she conducted "wet lab" research combining mathematics and cancer biology to improve cancer treatment modeling. In 2004, she received a $10 million grant from the National Aeronautics and Space Administration (NASA) and became the principal investigator at the Center for Cancer Systems Biology at Tufts University School of Medicine. In addition, she has directed review and research programs for the U.S. Department of Energy on low-dose effects.

Specialties:

Focuses on research in cancer systems biology, integrating cancer treatment with radiobiology studies.

Academic Achievements:

Dr. Hlatky has long been engaged in quantitative and empirical studies of the effects of radiation damage at the cellular and chromosomal levels, as well as the dynamics of tumor development. For radiation showing linear killing kinetics, she was the first to determine that any form of prolonged administration to asynchronous cell populations is asymptotically more suppressive than acute doses of the same magnitude [Hahnfeldt P and Hlatky L. Cellular resensitization during long-term dosing of heterogeneous cell populations. Radiation Research 150:681-687, 1998]. She subsequently demonstrated that uniform dosing is optimal in this regard [Hahnfeldt P, Folkman J, and Hlatky L. Minimizing long-term tumor burden: rationale for metronomic chemotherapy dosing and its anti-angiogenic basis. J Theor Biol 220:545-554, 2003].

Her laboratory has extensive expertise in angiogenesis and was the first to show expression of the major angiogenic factor VEGF (Vascular Endothelial Growth Factor) in irradiated cells [Hlatky L, Hahnfeldt P, Tsionou C, Coleman CN. Vascular endothelial growth factor: environmental control and effect on angiogenesis. Br J Cancer 74 (Suppl XXVII): S151-6, 1996]. These early studies highlighted the role of endothelial and stromal cells in tumor radiation response. In the following decade, Dr. Hlatky's lab discovered many new inferences regarding angiogenesis and radiation response in tumor populations. Her lab demonstrated new relationships in the diversity of tumor population radiation responses under cellular stress, showing that the variability in cellular radiation responses under environmental stress (using self-imposed gradient ischemia across the population) decreases after simulated reperfusion and then sharply increases when oxygen/nutrients are reintroduced into cultures to mimic reperfusion [Hlatky L, Van Buren T, Hahnfeldt P. Quantifying intercellular radiation response heterogeneity in sandwich cultures using micronucleus expression. Int J Radiat Biol 67:541-8, 1995].

Her recent collaboration with Professor Rainer K. Sachs refuted the long-standing paradigm of chronic myeloid leukemia (CML)—a well-known radiation-induced cancer—arising from a single cell. When CML was considered to originate from two cells, they demonstrated that it statistically better fit the incidence data [Sachs RK, Johnsson K, Hahnfeldt P, Luo J, Chen A, Hlatky L. Multicellular origin of the progenitor cell crisis in chronic myeloid leukemia. Cancer Res 71(8):2838-47, 2011]. This study has profound implications for the role of intercellular interactions in carcinogenesis.

Society or Association Positions:

Principal Investigator, U.S. Center for Cancer Systems Biology

Educational Background:

Ph.D. in Physics and Biophysics, University of California, Berkeley

Research Directions:

● Carcinogenesis and tumor growth dynamics

● Radiobiology

● Translational research on microenvironmental influences

● DNA damage and repair

● Tumor angiogenesis

● Tumor-cell fusion

  • Previous:Stephen B Channey
  • Next:Dr. Ana Hernandez
Partners Our vision is to build a global healthcare ecosystem and work hand in hand for the better health of all mankind.
Find a recovery plan just for you.
Fill out the form immediately and
we'll call you back right away!
We will contact you through the phone number provided by you,
usually within 24 hours after your request.
Fill in your phone number and cancer and cell related
queries, and we will come to you immediately.
Medical Report*
    Yes     No
More Links
About Us
Company Introduction
Mission and Vision
Honors and Patents
Company Environment
Development History
China Placenta Resource Bank
News
Cell Frontier
Global Recruitment
Site Map
Refractory Diseases
Immune Reconstitution
Neural Reconstruction
Joint Reconstruction
Organ Reconstruction
Expert Team
Team Of Overseas Experts
Team Of Chinese Experts
Treatment Cases
Cases Of Immunity Reconstitution
Cases Of Neural Reconstruction
Cases Of Joint Reconstruction
Cases of Organ Reconstruction
Functional Food
Zhi Yi Sheng
Yuan Fu Selenium
IACECELL ESCTS Cell Capsules
Hirudin Capsules
Hao Chang Wei
Du Tong
Cell Products
Cell Storage
Cell Preparation
Contact Us
0756-8800024
400-830-8005
International
Locations
& Offices
  • *Disclaimer:
  • Surgery can be highly effective in treating early-stage solid tumors, but they might not be applicable to advanced cancers. For physically weak patients with advanced cancer, minimally invasive treatment approach combined with radiotherapy and chemotherapy, along with immune cell therapy, can effectively minimize the damage and side effects caused by those treatment approaches, thus causing more effective treatment for each patient.
  • *Disclaimer:
  • The treatment effect varies from person to person. The information on United Life website is for reference only and cannot be used as a basis for medical diagnosis or treatment, nor is it intended as a substitute for professional medical advice for diagnosis and treatment. For more detailed information, please refer to the liability clauses.治疗效果是因人而异,联合生命网站信息仅供参考,不能作为医疗诊断和治疗依据,不能代替医生的诊断和治疗。更多详细信息,请查看责任条款。